
Yunsuk Choi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6216018/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling. PLoS ONE, 2022, 17, e0265958.	1.1	4
2	Clinical implications and genetic features of clonal cytopenia of undetermined significance compared to lowerâ€risk myelodysplastic syndrome. British Journal of Haematology, 2022, 198, 703-712.	1.2	6
3	Late complications and quality of life assessment for survivors receiving allogeneic hematopoietic stem cell transplantation. Supportive Care in Cancer, 2021, 29, 975-986.	1.0	20
4	Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas. Annals of Hematology, 2021, 100, 189-196.	0.8	2
5	Second allogeneic hematopoietic stem cell transplantation in patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation. Clinical Transplantation, 2021, 35, e14199.	0.8	4
6	LIGHT (TNFSF14) enhances osteogenesis of human bone marrow-derived mesenchymal stem cells. PLoS ONE, 2021, 16, e0247368.	1.1	4
7	Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial. International Journal of Hematology, 2021, 113, 851-860.	0.7	6
8	Association of serum hemoglobin level with the risk of carotid plaque beyond metabolic abnormalities among asymptomatic adults without major adverse clinical events: a cross-sectional cohort study. BMC Cardiovascular Disorders, 2021, 21, 35.	0.7	1
9	Changes in decision-making process for life-sustaining treatment in patients with advanced cancer after the life-sustaining treatment decisions-making act. BMC Palliative Care, 2021, 20, 63.	0.8	8
10	The c-Abl inhibitor, radotinib induces apoptosis in multiple myeloma cells via mitochondrial-dependent pathway. Scientific Reports, 2021, 11, 13198.	1.6	5
11	Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study. Korean Journal of Internal Medicine, 2021, 36, 194-204.	0.7	6
12	Effect of Stem Cell Source and Dose on Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Idiopathic Aplastic Anemia: Data from the Korean Aplastic Anemia Trials. Acta Haematologica, 2020, 143, 232-243.	0.7	4
13	"Teachable Moment†Effects of an Educational Program on Knowledge and Quality of Life of Korean Breast Cancer Survivors. Journal of Cancer Education, 2020, , 1.	0.6	0
14	Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death. BMC Cancer, 2020, 20, 1193.	1.1	8
15	Monosomal karyotype affecting outcomes of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. European Journal of Haematology, 2020, 105, 262-273.	1.1	3
16	Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL). Bone Marrow Transplantation, 2020, 55, 1466-1468.	1.3	2
17	CD45dimCD34+CD38â^'CD133+ cells have the potential as leukemic stem cells in acute myeloid leukemia. BMC Cancer, 2020, 20, 285.	1.1	13
18	Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia. Yonsei Medical Journal, 2020, 61, 452.	0.9	2

Yunsuk Choi

#	Article	IF	CITATIONS
19	Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantation. Korean Journal of Internal Medicine, 2020, 35, 429-437.	0.7	3
20	Pneumocephalus following fluoroscopy-guided lumbar epidural injection in elderly patients: two cases report and a review of Korean literatures - Two cases report Anesthesia and Pain Medicine, 2020, 15, 492-497.	0.5	0
21	Distinct Clinical Features of Plasma Cell Myeloma Patients Exhibiting Dysmorphic Plasma Cells: Association with More Plasma Cells at Diagnosis. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 662-672.	0.3	0
22	High-grade nodal marginal zone lymphoma with diffuse bone marrow involvement and IgM-type monoclonal paraproteinemia: a case report and review of the literature. Blood Research, 2019, 54, 229-231.	0.5	1
23	Bone marrow metastasis of small cell lung carcinoma with spontaneous tumor lysis syndrome without hepatic metastasis at diagnosis: first case report in Korea and review of literature. Blood Research, 2019, 54, 231-233.	0.5	3
24	Lenalidomide as a secondâ€line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome. British Journal of Haematology, 2019, 186, e151-e155.	1.2	2
25	Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e367-e373.	0.2	1
26	Radotinib inhibits mitosis entry in acute myeloid leukemia cells via suppression of Aurora kinase A expression. Tumor Biology, 2019, 41, 101042831984861.	0.8	11
27	Clinical Utility of 18F-Florbetaben PET for Detecting Amyloidosis Associated With Multiple Myeloma. Clinical Nuclear Medicine, 2019, 44, e503-e509.	0.7	10
28	Comparison of High Sensitivity and Conventional Flow Cytometry for Diagnosing Overt Paroxysmal Nocturnal Hemoglobinuria and Detecting Minor Paroxysmal Nocturnal Hemoglobinuria Clones. Annals of Laboratory Medicine, 2019, 39, 150-157.	1.2	2
29	Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS). Blood, 2019, 134, 1643-1643.	0.6	2
30	Expression and prognostic significance of microRNAs in Korean patients with myelodysplastic syndrome. Korean Journal of Internal Medicine, 2019, 34, 390-400.	0.7	14
31	Myositis in bilateral calves mimicking lymphoma on interim PET/CT in a patient with T-lymphoblastic lymphoma. Japanese Journal of Clinical Oncology, 2018, 48, 499-500.	0.6	1
32	Rhein augments ATRA-induced differentiation of acute promyelocytic leukemia cells. Phytomedicine, 2018, 49, 66-74.	2.3	14
33	Estimation of the effect-site equilibration rate constant using the time-to-peak effect of muscle relaxants measured by train-of-four stimulation during general anesthesia induction. Korean Journal of Anesthesiology, 2018, 71, 113-119.	0.9	0
34	Allogeneic Hematopoietic Cell Transplantation for Severe Idiopathic Aplastic Anemia Older Than 40y. Blood, 2018, 132, 3876-3876.	0.6	0
35	Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission. Biology of Blood and Marrow Transplantation, 2017, 23, 1555-1566.	2.0	21
36	Radotinib induces high cytotoxicity in c-KIT positive acute myeloid leukemia cells. European Journal of Pharmacology, 2017, 804, 52-56.	1.7	10

Yunsuk Choi

#	Article	IF	CITATIONS
37	Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death. Scientific Reports, 2017, 7, 15278.	1.6	54
38	Trend and treatment patterns of aplastic anemia in Korea, pure red cell aplasia and myelodysplastic syndrome in Korea: a nation-wide analysis. International Journal of Hematology, 2017, 106, 500-507.	0.7	2
39	Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type. Annals of Hematology, 2017, 96, 25-31.	0.8	81
40	Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5. Oncotarget, 2017, 8, 11748-11762.	0.8	14
41	Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology, 2017, 35, 2754-2763.	0.8	65
42	Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells. Oncotarget, 2017, 8, 41387-41400.	0.8	9
43	Mass-Forming Extramedullary Hematopoiesis in Multiple Myeloma: ¹⁸ F-FDG PET/CT is useful in Excluding Extramedullary Myeloma Involvement. Tumori, 2016, 102, S116-S118.	0.6	4
44	LIGHT (TNFSF14) Increases the Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem Cells. PLoS ONE, 2016, 11, e0166589.	1.1	17
45	A prospective, multicenter phase <scp>II</scp> study of continuous infusion of <scp>FLAG</scp> for patients older than 60Âyr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial. European Journal of Haematology, 2016, 96, 188-197.	1.1	11
46	Metastatic prostate cancer initially presenting as chylothorax: A case report. Molecular and Clinical Oncology, 2016, 4, 1009-1012.	0.4	1
47	<scp>BK</scp> polyomavirus encephalitis in a patient with thrombotic microangiopathy after an allogeneic hematopoietic stem cell transplant. Transplant Infectious Disease, 2016, 18, 950-953.	0.7	7
48	Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors. European Journal of Pharmacology, 2016, 789, 280-290.	1.7	13
49	Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 159-166.	0.7	1
50	Peripheral T cell lymphomas in elderly patients: a retrospective analysis from the Hematology Association of South East Korea (HASEK). Annals of Hematology, 2016, 95, 619-624.	0.8	4
51	Angioimmunoblastic T-Cell Lymphoma in a Patient with Klinefelter Syndrome. American Journal of Case Reports, 2016, 17, 529-534.	0.3	3
52	Prognostic role of <scp>FEV</scp> ₁ for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. Clinical Transplantation, 2015, 29, 1133-1139.	0.8	21
53	<i>JAK2</i> V617F, <i>MPL</i> , and <i>CALR</i> Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis. Journal of Korean Medical Science, 2015, 30, 882.	1.1	16
54	Radotinib Induces Apoptosis of CD11b+ Cells Differentiated from Acute Myeloid Leukemia Cells. PLoS ONE, 2015, 10, e0129853.	1.1	18

Үимѕик Сноі

#	Article	IF	CITATIONS
55	Monosomal karyotype in acute myeloid leukemia and the role of allogeneic hematopoietic cell transplantation. Annals of Hematology, 2015, 94, 795-801.	0.8	4
56	Up-Front Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Arising from the Myelodysplastic Syndrome. Acta Haematologica, 2015, 133, 183-192.	0.7	3
57	Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome. European Journal of Haematology, 2015, 94, 546-553.	1.1	11
58	Treatment Outcome and Prognostic Factors of Korean Patients with Chronic Lymphocytic Leukemia: Multicenter Retrospective Study. Blood, 2014, 124, 5669-5669.	0.6	0
59	Prognostic implications of CD14 positivity in acute myeloid leukemia arising from myelodysplastic syndrome. International Journal of Hematology, 2013, 97, 246-255.	0.7	7
60	Clinical Characteristics and Prognostic Factors of Adenoid Cystic Carcinoma of the Head and Neck. Laryngoscope, 2013, 123, 1430-1438.	1.1	38
61	Single nucleotide polymorphism of Wilms' tumor 1 gene rs16754 in Korean patients with cytogenetically normal acute myeloid leukemia. Annals of Hematology, 2012, 91, 671-677.	0.8	17
62	Immediate Allogeneic Hematopoietic Cell Transplantation (HCT) in Acute Myeloid Leukemia (AML) Arising From Myelodysplastic Syndrome (MDS). Blood, 2011, 118, 2031-2031.	0.6	0
63	Validation of New Prognostic Model Including Comorbidities in Patients with Myleodysplastic Syndrome Receiving Hypomethylating Therapy. Blood, 2011, 118, 1708-1708.	0.6	0
64	A Case Report of Rituximab Therapy for Recurrent Thrombotic Thrombocytopenia Purpura. The Korean Journal of Hematology, 2009, 44, 193.	0.7	0
65	Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia: Role of the NPM1 Mutations May Be Different in Different Races Blood, 2009, 114, 4684-4684.	0.6	0
66	Timing of G-CSF Injection for Effective Autologous Stem Cell Collection. Blood, 2008, 112, 4439-4439.	0.6	0